Abstract: The present disclosure provides pharmaceutical compositions of remdesivir that may be administered by inhalation. These compositions may allow the achievement of a therapeutically effective dose of remdesivir directly to the lungs. These compositions may be used to treat one or more diseases or disorders such as a viral infection like an infection of a coronavirus.

Abstract: In some aspects, the present disclosure provides methods of preparing pharmaceutical compositions using an suspension based thin film freezing method to obtain inhalable compositions. These compositions may have a higher homogeneity compared to compositions prepared using conventional methods. These compositions may be used to treat or prevent one or more diseases or disorders.

Abstract: In some aspects, the present disclosure provides pharmaceutical compositions comprising particles, wherein individual particles of the composition comprise a combination of two or more active pharmaceutical ingredients selected from: (A) nintedanib; (B) pirfenidone; and/or (C) mycophenolic acid. These compositions may be formulated for administration via inhalation. In some aspects, the present disclosure provides methods for preparing the pharmaceutical compositions of the present disclosure and methods of treating or preventing a disease or disorder using the pharmaceutical compositions of the present disclosure.

Abstract: Dry powder compositions comprising biologically active polynucleotide molecules and methods for the manufacture of such dry powders are provided. In some aspects, dry powders of the embodiment comprise expressible or regulatory (e.g., siRNA) polynucleotide molecules complexed with nanoparticles. Dry powders comprising viable virus and bacteria are also provided.

Abstract: Provided herein are compositions comprising caveolin-1 (Cav-1) peptides. Further provided are methods of using the Cav-1 peptides for the treatment of lung infections or acute or chronic lung injury, particularly lung fibrosis.